Unicycive Therapeutics Inc [NASDAQ: UNCY] price surged by 14.88 percent to reach at $0.09.
The one-year UNCY stock forecast points to a potential upside of 88.93. The average equity rating for UNCY stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Unicycive Therapeutics Inc [UNCY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for UNCY shares is $6.14 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on UNCY stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Unicycive Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 04, 2024.
The Average True Range (ATR) for Unicycive Therapeutics Inc is set at 0.06 The Price to Book ratio for the last quarter was 2.38, with the Price to Cash per share for the same quarter was set at 0.31.
UNCY Stock Performance Analysis:
Unicycive Therapeutics Inc [UNCY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 33.08. With this latest performance, UNCY shares gained by 40.67% in over the last four-week period, additionally sinking by -18.99% over the last 6 months – not to mention a rise of 25.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for UNCY stock in for the last two-week period is set at 73.90, with the RSI for the last a single of trading hit 80.54, and the three-weeks RSI is set at 69.58 for Unicycive Therapeutics Inc [UNCY]. The present Moving Average for the last 50 days of trading for this stock 0.4561, while it was recorded at 0.5757 for the last single week of trading, and 0.7626 for the last 200 days.
Insight into Unicycive Therapeutics Inc Fundamentals:
Unicycive Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.61 and a Current Ratio set at 3.61.
UNCY Stock EPS
With the latest financial reports released by the company, Unicycive Therapeutics Inc posted -0.13/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for UNCY.
Unicycive Therapeutics Inc [UNCY] Institutonal Ownership Details
There are presently around $38.24%, or 41.00%% of UNCY stock, in the hands of institutional investors. The top three institutional holders of UNCY stocks are: VIVO CAPITAL, LLC with ownership of 3.47 million shares, which is approximately 9.9395%. LOGOS GLOBAL MANAGEMENT LP, holding 3.47 million shares of the stock with an approximate value of $$1.74 million in UNCY stocks shares; and LOGOS GLOBAL MANAGEMENT LP, currently with $$1.41 million in UNCY stock with ownership which is approximately 8.0783%.
